BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, parallel group, multicentre global phase 3
clinical study to evaluate the efficacy, safety and immunogenicity of BOW015
(infliximab-EPIRUS) compared to Remicade in subjects with active Rheumatoid Arthritis (RA)
despite Methotrexate (MTX) therapy.